Interferon Alpha-2a for Proliferative Diabetic Retinopathy after Complete Laser Panretinal Photocoagulation Treatment

Ophthalmic Surgery Lasers and Imaging

Volumn 35, Issue 1, 2004, Pages 16-22

  Leibovitch, Igal ^a   Loewenstein, Anat ^a   Alster, Yair ^a   Rosenblatt, Irit ^b   Lazar, Moshe ^a   Yassur, Yuval ^b   Rubinstein, Ardon ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LASER COAGULATION; MALAISE; MALE; PILOT STUDY; PRIORITY JOURNAL; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 0347593954     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/1542-8877-20040101-05     Document Type: Article

References (42)

1. Department of Health, Education and Welfare. Report of the National Commission of Diabetes to the Congress of the United States: The Long-Range Plan to Combat Diabetes, vol. 1. Bethesda, MD: Department of Health, Education and Welfare; 1976:1018.
2. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. DRS Report No. 8. Ophthalmology. 1981;88:583-600.
3. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report 9. Ophthalmology. 1991;98(suppl 5):766-785.
4. Vine AK. The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy. Ophthalmology. 1985;92:1532-1537.
5. Davis MD. Proliferative diabetic retinopathy. In: Ryan SJ, Schachat AP, Murphy RP, eds. Retina, 2nd ed. St. Louis, MO: Mosby; 1994:1350-1353.
6. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology. 1988;95:1307-1320.
7. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
8. Drixler TA, Rinkes IH, Ritchie ED, et al. Angiostatin inhibits pathological but not physiological retinal angiogenesis. Invest Ophthalmol Vis Sci. 2001;42:3325-3330.
9. Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol. 2002;160:1097-1103.
10. Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002;160:1683-1693.
11. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 1989;320:1211-1212.
12. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442-447.
13. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effect on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-5161.
14. Tsuruoka N, Sugiyama M, Tawaragi Y, et al. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-γ. Biochem Biophys Res Commun. 1988;155:429-435.
15. Stewart WE II, Sarkar FH, Taira H, Hall A, Nagata S, Weismann C. Comparisons of several biological and physicochemical properties of human leukocyte interferons produced by human leukocytes and by E. coli. Gene. 1980;11:181-186.
16. Gresser I. Biologic effects of interferons. J Invest Dermatol. 1990;95(suppl 6):66S-71S.
17. Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons: mechanisms of action and clinical applications. JAMA. 1991;266:1375-1383.
18. Attallah AM, Zoon K, Folks T, Huntington J, Yeatman TJ. Multiple biological activities of homogeneous human alpha interferon. Infect Immun. 1981;34:1068-1070.
19. Brouty-Boye D, Zetter B. Inhibition of cell motility by interferon. Science. 1980;208:516-518.
20. Real TX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol. 1986;4:544-551.
21. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:671-676.
22. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989;320:1197-1200.
23. Orchard PJ, Smith CM III, Woods WG, Day DL, Dehner LP, Shapiro R. Treatment of haemangioendotheliomas with alpha interferon. Lancet. 1989;2:565-567.
24. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991;118:59-66.
25. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
26. Stiehm ER, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. Interferon: immunobiology and clinical significance. Ann Intern Med. 1982;96:80-93.
27. Streuli M, Nagata S, Weissmann C. At least three human type alpha interferons: structure of alpha 2. Science. 1980;209:1343-1347.
28. Miller WJ, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology. 1993;100:9-14.
29. Skowsky WR, Siddiqui T, Hodgetts D, et al. A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effect and ophthalmologic effects. J Diabet Complications. 1996;10:94-99.
30. Fung WE. Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol. 1991;112:349-350.
31. Gillies MC, Sarks JP, Beaumont PE, et al. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b. Br J Ophthalmol. 1993;77:759-765.
32. Engler CB, Sander B, Koefoed P, et al. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration: a pilot investigation. Acta Ophthalmol. 1993;71:27-31.
33. Kirkpatrick JNP, Dick AD, Forrester JV. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. Br J Ophthalmol. 1993;77:766-770.
34. Engler C, Sander B, Villumsen J, Lund-Andersen H. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. Br J Ophthalmol. 1994;78:749-753.
35. Jaakkola A, Anttila PM, Immonen I. Interferon alpha-2a in the treatment of exudative senile macular degeneration. Acta Ophthalmol. 1994;72:545-549.
36. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115:865-872.
37. Elner SG, Strieter R, Bian ZM, et al. Interferon-induced protein 10 and interleukin 8 C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:1597-1601.
38. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111:350-356.
39. Soushi S, Kobayashi F, Obazawa H, et al. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. Nippon Ganka Gakkai Zasshi. 1996;100:69-76.
40. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology. 1991;98:1575-1579.
41. Vine AK. The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy. Ophthalmology. 1985;92:1532-1537.
42. Kaiser RS, Maguire MG, Grunwald JE, et al. One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol. 2000;129:178-185.